MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/2326-6066.cir-23-1105

Медицинская библиотека · Cancer immunology research · 2024

Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers.

Praharaj Monali, Shen Fan, Lee Alex J, Zhao Liang, Nirschl Thomas R, Theodros Debebe, Singh Alok K, Wang Xiaoxu, Adusei Kenneth M, Lombardo Kara A, Williams Raekwon A, Sena Laura A, Thompson Elizabeth A, Tam Ada, Yegnasubramanian Srinivasan, Pearce Edward J, Leone Robert D, Alt Jesse, Rais Rana, Slusher Barbara S, Pardoll Drew M, Powell Jonathan D, Zarif Jelani C

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Glutamine metabolism in tumor microenvironments critically regulates antitumor immunity. Using the glutamine-antagonist prodrug JHU083, we report potent tumor growth inhibition in urologic tumors by JHU083-reprogrammed tumor-associated macrophages (TAMs) and tumor-infiltrating monocytes. We show JHU083-mediated glutamine antagonism in tumor microenvironments induced by TNF, proinflammatory, and mTORC1 signaling in intratumoral TAM clusters. JHU083-reprogrammed TAMs also exhibited increased tumor cell phagocytosis and diminished proangiogenic capacities. In vivo inhibition of TAM glutamine consumption resulted in increased glycolysis, a broken tricarboxylic acid (TCA) cycle, and purine metabolism disruption. Although the antitumor effect of glutamine antagonism on tumor-infiltrating T cells was moderate, JHU083 promoted a stem cell-like phenotype in CD8+ T cells and decreased the abundance of regulatory T cells. Finally, JHU083 caused a global shutdown in glutamine-utilizing metabolic pathways in tumor cells, leading to reduced HIF-1α, c-MYC phosphorylation, and induction of tumor cell apoptosis, all key antitumor features. Altogether, our findings demonstrate that targeting glutamine with JHU083 led to suppressed tumor growth as well as reprogramming of immunosuppressive TAMs within prostate and bladder tumors that promoted antitumor immune responses. JHU083 can offer an effective therapeutic benefit for tumor types that are enriched in immunosuppressive TAMs.

Для цитирования: Praharaj Monali, Shen Fan, Lee Alex J, Zhao Liang, Nirschl Thomas R, Theodros Debebe, Singh Alok K, Wang Xiaoxu, Adusei Kenneth M, Lombardo Kara A, Williams Raekwon A, Sena Laura A, Thompson Elizabeth A, Tam Ada, Yegnasubramanian Srinivasan, Pearce Edward J, Leone Robert D, Alt Jesse, Rais Rana, Slusher Barbara S, Pardoll Drew M, Powell Jonathan D, Zarif Jelani C. Metabolic Reprogramming of Tumor-Associated Macrophages Using Glutamine Antagonist JHU083 Drives Tumor Immunity in Myeloid-Rich Prostate and Bladder Cancers.. Cancer immunology research. 2024. DOI: 10.1158/2326-6066.cir-23-1105.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.